Published Mon, 15 Apr 2019 05:32:14 -0400 on Seeking Alpha
A few days ago, I published an article to this site discussing one of the better biotechnology funds, which is an area of the economy that could quite easily have a very bright future. However, the entire healthcare industry itself is likely to prove quite promising due to certain conditions becoming more prevalent as well as demographic shifts that are pushing a greater proportion of the population into age brackets in which they are likely to require the services of the healthcare industry. I have in the past discussed one of the ways that I am playing these trends, the Tekla World Healthcare Fund (THW), but that was several months ago. Therefore, I feel that the time is appropriate to discuss some of the changes that the fund has made so that we can remain aware of exactly where our money is invested.
About The Fund
According to the fund's web page, the Tekla World Healthcare Fund has the objective of seeking current income and long-term capital appreciation by investing in both equity and debt securities of companies in the healthcare industry. This differs somewhat from Tekla Life Sciences Investors (HQL), the aforementioned biotechnology fund, in that the latter fund is solely interested in generating capital appreciation. Most closed-end funds do focus both on the generation of capital gains and current income, though, so THW is far from unique in this case.
As the name implies, the Tekla World Healthcare Fund invests in companies from all around the world and does... Read more
|Stock name||Last trade||P/E||Earnings/Share||Dividend/Share||Dividend yield|
|H&Q LIFE SCIENCES INVESTORS||16.24||0.0||0.00||0.00||8.04|
|JOHNSON & JOHNSON||139.20||25.8||5.40||3.60||2.61|
Older articles featuring H&q Life Sciences Investors (HQL):Pace Of Dividend Cuts Accelerates In February 2019
Are CEF Investors Getting Suckered Into High Yields?
The Best Healthcare CEF For A Retiree To Receive A 7% Dividend
Share In Healthcare & Biotech Gains With An 8.3% Yield
Interview: Long-Term Very High Dividend Picks From 9 Prominent Seeking Alpha Contributors
You Can Buy This 11.2% Yielding, Unleveraged Equity CEF Without Paying A Premium
7 Dividend Stocks For 2015
Tekla Life Sciences Investors Declares Stock Distribution
Equity CEFs: Don't Judge A CEF By Its Yield
First Quarter 2014 CEF Review And Outlook: Discounts, Yield, IPOs And Activist Activity